Dopamine

For other uses, see Dopamine (disambiguation).

Dopamine
Dopamine
General
Systematic name	4-(2-aminoethyl)benzene-1,2-diol
Other names	2-(3,4-dihydroxyphenyl)ethylamine; 3,4-dihydroxyphenethylamine; 3-hydroxytyramine; DA; Intropin Revivan; Oxytyramine
Molecular formula	C8H11NO2
SMILES	C1=CC(=C(C=C1CCN)O)O
Molar mass	153.178 g/mol
Appearance	white powder with distinctive smell
CAS number	[51-61-6]
Properties
Density and phase	? g/cm³, ?
Solubility in water	60.0 g/100 ml (? °C), solid
Melting point	128 °C (401 K)
Boiling point	? °C (? K)
Acidity (pKa)	?
Basicity (pKb)	?
Chiral rotation [α]D	?°
Viscosity	? cP at ? °C
Structure
Molecular shape	?
Coordination geometry	?
Crystal structure	?
Dipole moment	? D
Hazards
MSDS	External MSDS
Main hazards	?
NFPA 704	?
Flash point	? °C
R/S statement	R: 36/37/38 S: 26-36
RTECS number	UX1088000
Supplementary data page
Structure and properties	n, εr, etc.
Thermodynamic data	Phase behaviour Solid, liquid, gas
Spectral data	UV, IR, NMR, MS
Related compounds
Other anions	?
Other cations	?
Related ?	?
Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references

Dopamine is a chemical naturally produced in the body. In the brain, dopamine functions as a neurotransmitter, activating the five types of dopamine receptor - D1, D2, D3, D4 and D5, and their variants. Dopamine is also a neurohormone released by the hypothalamus. Its main function as a hormone is to inhibit the release of prolactin from the anterior lobe of the pituitary.

Dopamine can be supplied as a medication that acts on the sympathetic nervous system, producing effects such as increased heart rate and blood pressure. However, since dopamine cannot cross the blood-brain barrier, dopamine given as a drug does not directly affect the central nervous system. To increase the amount of dopamine in the brains of patients with diseases such as Parkinson's disease and Dopa-Responsive Dystonia, L-DOPA (levodopa), which is the precursor of dopamine, can be given, because L-dopa can cross the blood-brain barrier.

History

Dopamine was discovered by Arvid Carlsson and Jils-Ake Hillarp at the Laboratory for Chemical Pharmacology of the National Heart Institute of Sweden, in 1952. It was named Dopamine because it was a monoamine, and its synthetic precursor was 3,4-dihydroxyphenylalanine (L-DOPA). Arvid Carlsson won a share of the 2000 Nobel Prize in Physiology or Medicine for showing that dopamine is not just a precursor of noradrenaline and adrenaline, but a neurotransmitter as well.

Biochemistry

Dopamine has the chemical formula (C₆H₃(OH)₂-CH₂-CH₂-NH₂). Its chemical name is 4-(2-aminoethyl)benzene-1,2-diol and it is abbreviated "DA."

As a member of the catecholamine family, dopamine is a precursor to epinephrine (adrenaline) and norepinephrine (noradrenaline) in the biosynthetic pathways for these neurotransmitters.

Dopamine is biosynthesized in the body (mainly by nervous tissue and adrenal glands) first by the hydration of the amino acid L-tyrosine to L-DOPA via the enzyme tyrosine 3-monooxygenase, which is often known by its former name tyrosine hydroxylase, and then by the decarboxylation of DOPA by L-aromatic-amino-acid decarboxylase. In neurons, dopamine is packaged after synthesis into vesicles, which are then released in response to the presynaptic action potential. The inactivation mechanism of neurotransmission are 1) uptake via a specific transporter; 2) enzymatic breakdown; and 3) diffusion. Uptake back to the presynaptic neuron via the dopamine transporter is the major role in the inactivation of dopamine neurotransmission. The recycled dopamine will face either breakdown by an enzyme or be re-packaged into vesicles and reused.

Functions in the brain

Dopamine has many functions in the brain. Most importantly, dopamine is central to the reward system. Dopamine neurons are activated when an unexpected reward is presented. In nature, we learn to repeat behaviors that lead to unexpected rewards. Dopamine is therefore believed by many to provide a teaching signal to parts of the brain responsible for acquiring new motor sequences, i.e., behaviors.

In insects, a similar reward system exists, using octopamine, a chemical relative of dopamine. .

Movement

Via the dopamine receptors D1, D2, D3, D4 and D5, dopamine reduces muscle contraction. Shortage of dopamine, particularly the death of dopaminergic neurons in the nigrostriatal pathway, can cause Parkinson's disease, in which a person loses the ability to execute smooth, controlled movements. The phasic dopaminergic activation seems to be crucial with respect to a lasting internal encoding of motor skills (Beck, 2005).

Cognition and frontal cortex

In the frontal lobes, dopamine controls the flow of information from other areas of the brain. Dopamine disorders in this region of the brain can cause a decline in neurocognitive functions, especially memory, attention, and problem-solving. Reduced dopamine concentrations in the prefrontal cortex are thought to contribute to attention deficit disorder and some symptoms of schizophrenia. Conversely, anti-psychotic medications rely on their inhibition of dopamine uptake and are used in the treatment of positive symptoms in schizophrenia.

Regulating prolactin secretion

Dopamine is the primary neuroendocrine regulator of the secretion of prolactin from the anterior pituitary gland. Dopamine produced by neurons in the arcuate nucleus of the hypothalamus is secreted into the hypothalamo-hypophysial blood vessels of the median eminence, which supply the pituitary gland. The lactotrope cells that produce prolactin, in the absence of dopamine, secrete prolactin continuously; dopamine inhibits this secretion.

Motivation and pleasure

Dopamine is commonly associated with the pleasure system of the brain, providing feelings of enjoyment and reinforcement to motivate a person proactively to perform certain activities. Dopamine is released (particularly in areas such as the nucleus accumbens and striatum) by naturally rewarding experiences such as food, sex, use of certain drugs and neutral stimuli that become associated with them. This theory is often discussed in terms of drugs (such as cocaine and amphetamines), which seem to be directly or indirectly related to the increase of dopamine in these areas, and in relation to neurobiological theories of chemical addiction, arguing that these dopamine pathways are pathologically altered in addicted persons. However, cocaine and amphetamine influence separate mechanisms of action.

Cocaine is a dopamine transporter blocker that competitively inhibits dopamine uptake to increase the lifetime of dopamine and augments an overabundance of dopamine (an increase of up to 150%) within the parameters of the dopamine neurotransmitters. Like cocaine, amphetamines increase the concentration of dopamine in the synaptic gap, but by a different mechanism. Amphetamines are similar in structure to dopamine, and so can enter the terminal button of the presynaptic neuron via its dopamine transporters as well as by diffusing through the neural membrane directly. When entering inside the presynaptic neuron, amphetamines force the dopamine molecules out of their storage vesicles and expel them into the synaptic gap by making the dopamine transporters work in reverse. Dopamine's role in experiencing pleasure has been questioned by several researchers. It has been argued that dopamine is more associated with anticipatory desire and motivation (commonly referred to as "wanting") as opposed to actual consummatory pleasure (commonly referred to as "liking"). Dopamine is not released when unpleasant or aversive stimuli are encountered, and so motivates towards the pleasure of avoiding or removing the unpleasant stimuli.

Recent research suggests that the firing of dopamine neurons is a motivational chemical as a result of reward-anticipation. This is based on evidence that, when a reward is perceived to be greater than expected, the firing of certain dopamine neurons increases, which correspondingly increases desire or motivation toward the reward.

Clues to dopamine's role in motivation, desire and pleasure have come from studies performed on animals. In one such study rats were depleted of dopamine by up to 99% in the nucleus accumbens and neostriatum using 6-hydroxydopamine. With this large reduction in dopamine, the rats would no longer eat by their own volition. The researchers then force fed the rats food and noted whether they had the proper facial expressions indicating whether they liked or disliked it. The researchers of this study concluded that the reduction in dopamine did not reduce the rat's consummatory pleasure, only the desire to actually eat. In another study, mutant hyperdopaminergic (increased dopamine) mice show higher "wanting" but not "liking" of sweet rewards.

In humans, though, drugs that reduce dopamine activity (neuroleptics, [eg. some antipsychotics) have been shown to reduce motivation as well as cause anhedonia (the inability to experience pleasure). Conversely the selective D2/D3 agonists pramipexole and ropinirole have anti-anhedonic properties as measured by the Snaith-Hamilton Pleasure Scale. (The Snaith-Hamilton-Pleasure-Scale (SHAPS), introduced in English in 1995, assesses self-reported anhedonia in psychiatric patients.)

Opioid and cannabinoid transmission instead of dopamine may modulate consummatory pleasure and food palatability(liking). This could explain why animals "liking" of food is independent of brain dopamine concentration. Other consummatory pleasures, however, may be more associated with dopamine. One study found that both anticipatory and consummatory measures of sexual behavior (male rats) were disrupted by DA receptor antagonists. Libido can be increased by drugs that affect dopamine but not by drugs that affect opioid peptides or other neurotransmitters.

Sociability is also closely tied to dopamine neurotransmission. Low D2 receptor binding is found in people with social anxiety. Traits common to negative schizophrenia (social withdrawal, apathy, anhedonia) are thought to be related to a hypodopaminergic state in certain areas of the brain. In instances of bipolar, manic subjects can become hypersocial as well as hypersexual. This is also credited to an increase in dopamine, because mania alleviates from dopamine blocking antipsychotics.

Research suggests a crucial role of dopamine in reward systems and anticipation of pleasure. Dopamine may also have a role in the salience ('noticeableness') of perceived objects and events, with potentially important stimuli such as: 1) rewarding things or 2) dangerous or threatening things seeming more noticeable or important. This hypothesis argues that dopamine assists decision-making by influencing the priority, or level of desire, of such stimuli to the person concerned.

Pharmacological blockade of brain dopamine receptors increases rather than decreases drug-taking behavior. Since blocking dopamine decreases desire, the increase in drug taking behavior may be seen as not a chemical desire but as a deeply psychological desire to just 'feel something'.

Deficits in dopamine levels are implicated in Attention-deficit hyperactivity disorder(ADHD), and stimulant medications used to successfully treat the disorder increase dopamine neurotransmitter levels, leading to decreased symptoms.

Links to psychosis

Main article: dopamine hypothesis of psychosis

Disruption to the dopamine system has also been strongly linked to psychosis and schizophrenia. Dopamine neurons in the mesolimbic pathway are particularly associated with these conditions. This is partly due to the discovery of a class of drugs called the phenothiazines (which block D₂ dopamine receptors) that can reduce psychotic symptoms, and partly due to the finding that drugs such as amphetamine and cocaine (which are known to greatly increase dopamine levels) can cause psychosis. Because of this, most modern antipsychotic medication is designed to block dopamine function to varying degrees.

Depression

Dopamine is a neurotransmitter that is involved in depression. Amphetamines and Dopamine reuptake inhibitors have potent anti-depressant effects but these drugs quickly lose their benefit after they deplete dopamine levels in the brain.

Antidepressants appear to primarily enhance serotonergic neurotransmission during preliminary drug administration. However it takes several weeks for the antidepressant effect to be noticed. This late effect of antidepressants is thought to involve the indirect serotonergic modulation of dopaminergic neurotransmission.

However, there are Dopamine reuptake inhibitors that are used to treat depression such as bupropion (Zyban/Wellbutrin).

Therapeutic use

Main article: L-DOPA

Levodopa is a dopamine precursor used to treat Parkinson's disease. It is typically co-administered with an inhibitor of peripheral decarboxylation (DDC, dopa decarboxylase), such as carbidopa or benserazide. Inhibitors of alternative metabolic route for dopamine by catechol-O-methyl transferase are also used. These include entacapone and tolcapone.

Dopamine is also used as an inotropic drug in patients with shock to increase cardiac output and blood pressure.

Major pathways

• Mesocortical pathway
• Mesolimbic pathway
• Nigrostriatal pathway
• Tuberoinfundibular pathway

See also

• Addiction
• Amphetamine
• Antipsychotic
• Catecholamine
• Catechol-O-methyl transferase
• Cocaine
• Dopamine hypothesis of schizophrenia
• Dopamine reuptake inhibitors
• Methylphenidate
• Neurotransmitter
• Parkinson's disease
• Prolactinoma
• Schizophrenia
• Selegiline

External links

• CID 681 from PubChem
• DrugBank APRD00085

• http://learn.genetics.utah.edu/units/addiction/drugs/Mouse%20Party.swf – animation on how drugs affect the CNS